Medicus Pharma (NASDAQ:MDCX) Price Target Raised to $20.00

Medicus Pharma (NASDAQ:MDCX) had its price objective hoisted by Maxim Group from $10.00 to $20.00 in a research report released on Thursday,Benzinga reports. Maxim Group currently has a buy rating on the stock.

Several other equities research analysts have also weighed in on MDCX. D. Boral Capital reissued a “buy” rating and issued a $14.00 price objective on shares of Medicus Pharma in a report on Monday, April 28th. D Boral Capital upgraded shares of Medicus Pharma to a “strong-buy” rating in a research report on Monday, April 14th.

Medicus Pharma Stock Performance

MDCX opened at $4.59 on Thursday. Medicus Pharma has a twelve month low of $1.80 and a twelve month high of $6.00. The company has a 50-day moving average of $3.65.

Medicus Pharma (NASDAQ:MDCX) last posted its quarterly earnings data on Friday, March 28th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.14. As a group, research analysts anticipate that Medicus Pharma will post -1.14 earnings per share for the current fiscal year.

Institutional Trading of Medicus Pharma

An institutional investor recently bought a new position in Medicus Pharma stock. Private Advisor Group LLC bought a new stake in shares of Medicus Pharma Ltd. (NASDAQ:MDCX) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 56,750 shares of the company’s stock, valued at approximately $211,000. Private Advisor Group LLC owned approximately 0.42% of Medicus Pharma as of its most recent SEC filing.

Medicus Pharma Company Profile

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.